Active hexose correlated compound

background

Active hexose correlated compound (AHCC) is an alpha-glucan-rich dietary supplement extracted from Basidiomycota mushrooms, such as shiitake (Lentinula edodes).
AHCC is thought to stimulate the immune system and to reduce the adverse effects of chemotherapy. AHCC was developed in Japan in 1992 and may have antioxidant and anticancer activity, prevent the onset of diabetes, and prevent liver injury.

Related Terms

Activated hemicellulose, adenosine, AHCC-FD, alpha-1,4-glucan, amino acids, arginine, basidiomycete fungus, basidiomycete mushroom, Basidiomycetes, Basidiomycota mushroom, basidiomycotina extract, beta-glucan, choline, copper, folate, functional food, glutamic acid, glycoproteins, ImmPower™, Immunomax®, Lentinula edodes, leucine, lipids, magnesium, minerals, mycelia extract, niacin, oligosaccharides, pantothenic acid, phosphorus, potassium, selenium.

evidence table

These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider.
 
Cancer (general) (Grade: C)
Preliminary research suggests that active hexose correlated compound (AHCC), either alone or in combination with known anticancer therapies, improves various markers of cancer. Additional research in this area is warranted.
Cancer (prognosis and quality of life) (Grade: C)
AHCC has been shown to reduce chemotherapy-related side effects and enhance antitumor effects. Early evidence suggests that AHCC supplementation may improve the prognosis of cancer patients. However, there are not enough data to make a conclusion. Further research is needed.
Diabetes (Grade: C)
Early evidence suggests that AHCC intake may improve glucose control in patients with diabetes. However, data remain insufficient upon which to base a conclusion. Further research is required.
Hepatitis (Grade: C)
In people with hepatitis, preliminary research suggests that AHCC taken alone or in combination with known antiviral agents lowers levels of hepatitis C virus (HCV) RNA and hepatitis B antigen, respectively. Further research in this area is warranted before any firm conclusions can be made.
Idiopathic thrombocytopenic purpura (rash from low blood platelet count) (Grade: C)
Preliminary evidence suggests that AHCC increases platelet count and helps blood-related symptoms of idiopathic thrombocytopenic purpura (ITP), such as bruises and petechiae. However, due to the lack of high-quality research in this area, further research is warranted.
Immune function (Grade: C)
Early evidence suggests that AHCC intake may improve the immune response. However, data remain insufficient upon which to base a conclusion. Further research is needed.
Liver function (Grade: C)
Preliminary research suggests that AHCC improves liver function in people with nonviral liver conditions. Although this is promising, additional research in this area is necessary to substantiate early findings.